Side-by-side comparison of AI visibility scores, market position, and capabilities
World's largest online therapy platform, 30,000+ licensed therapists, Sunnyvale CA, owned by Teladoc Health. Consumer-focused text, phone, and video therapy.
BetterHelp is a Sunnyvale, California-based online therapy platform founded in 2013 and acquired by Teladoc Health in 2015. The platform is the world's largest online therapy service, with more than 30,000 licensed therapists and counselors available to members across the United States and internationally. BetterHelp is a direct-to-consumer service, allowing individuals to sign up, complete a brief matching questionnaire, and be paired with a therapist within days.\n\nMembers communicate with their therapist through multiple formats including text messaging, live chat, phone calls, and video sessions, offering a level of flexibility and asynchronous access that traditional therapy cannot match. Subscriptions are priced on a weekly or monthly basis with financial assistance available for lower-income members. BetterHelp has heavily invested in consumer brand awareness through podcast advertising and influencer partnerships, making it one of the most recognized names in consumer mental health.\n\nBetterHelp operates as part of Teladoc Health's mental health division alongside Teladoc's other behavioral health offerings, and the parent company's scale provides infrastructure and insurance relationship advantages. Despite facing regulatory scrutiny and advertiser criticism around messaging practices in 2022–2023, BetterHelp remains the dominant player in direct-to-consumer online therapy by volume of active clients and therapist network size.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.